On Tuesday, Denali Therapeutics Inc (NASDAQ: DNLI) was 0.73% up from the session before settling in for the closing price of $24.50. A 52-week range for DNLI has been $14.56 – $33.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 264.19% over the past five years. When this article was written, the company’s average yearly earnings per share was at -162.14%. With a float of $124.57 million, this company’s outstanding shares have now reached $138.39 million.
Let’s look at the performance matrix of the company that is accounted for 445 employees. In terms of profitability, gross margin is 102.06%, operating margin of 165.42%, and the pretax margin is 140.13%.
Denali Therapeutics Inc (DNLI) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Denali Therapeutics Inc stocks. The insider ownership of Denali Therapeutics Inc is 13.45%, while institutional ownership is 88.60%. The most recent insider transaction that took place on Nov 11 ’24, was worth 1,932,665. In this transaction Director of this company sold 59,441 shares at a rate of $32.51, taking the stock ownership to the 9,220 shares. Before that another transaction happened on Nov 07 ’24, when Company’s COFO and Secretary sold 15,558 for $29.91, making the entire transaction worth $465,286. This insider now owns 178,066 shares in total.
Denali Therapeutics Inc (DNLI) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -162.14% per share during the next fiscal year.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
You can see what Denali Therapeutics Inc (DNLI) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 9.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.76, a number that is poised to hit -0.82 in the next quarter and is forecasted to reach -2.85 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Denali Therapeutics Inc (NASDAQ: DNLI) saw its 5-day average volume 1.23 million, a positive change from its year-to-date volume of 1.07 million. As of the previous 9 days, the stock’s Stochastic %D was 15.38%. Additionally, its Average True Range was 1.36.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 36.35%, which indicates a significant increase from 11.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.00% in the past 14 days, which was higher than the 54.24% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $27.64, while its 200-day Moving Average is $22.68. Nevertheless, the first resistance level for the watch stands at $25.02 in the near term. At $25.37, the stock is likely to face the second major resistance level. The third major resistance level sits at $25.79. If the price goes on to break the first support level at $24.25, it is likely to go to the next support level at $23.83. The third support level lies at $23.48 if the price breaches the second support level.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
There are 143,922K outstanding shares of the company, which has a market capitalization of 3.55 billion. As of now, sales total 330,530 K while income totals -145,220 K. Its latest quarter income was 0 K while its last quarter net income were -107,190 K.
